{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:13:05Z","timestamp":1778728385759,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"UCB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04467-8","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:24:39Z","timestamp":1763717079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Using skin biopsies to measure target occupancy of anti-fibrotic molecules: assay development and application for zampilimab in a primate model of chronic kidney disease and in healthy human volunteers"],"prefix":"10.1186","volume":"27","author":[{"given":"Linghong","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowann","family":"Bowcutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Bigley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Ogg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey I.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy S.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"3","key":"4467_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.pharmthera.2009.03.002","volume":"122","author":"S Grimwood","year":"2009","unstructured":"Grimwood S, Hartig PR. Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol Ther. 2009;122(3):281\u2013301.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"4467_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1021\/acsmedchemlett.9b00570","volume":"11","author":"J Stefaniak","year":"2020","unstructured":"Stefaniak J, Huber KVM. Importance of quantifying drug-target engagement in cells. ACS Med Chem Lett. 2020;11(4):403\u20136.","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"4467_CR3","first-page":"1","volume":"34","author":"RD Pentz","year":"2012","unstructured":"Pentz RD, Harvey RD, White M, Farmer ZL, Dashevskaya O, Chen Z, et al. Research biopsies in phase I studies: views and perspectives of participants and investigators. IRB. 2012;34(2):1\u20138.","journal-title":"IRB"},{"issue":"3","key":"4467_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00467-015-3104-8","volume":"31","author":"EA Hartung","year":"2016","unstructured":"Hartung EA. Biomarkers and surrogate endpoints in kidney disease. Pediatr Nephrol. 2016;31(3):381\u201391.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"4467_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1152\/physrev.00019.2013","volume":"94","author":"RL Eckert","year":"2014","unstructured":"Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GV, Mehta K. Transglutaminase regulation of cell function. Physiol Rev. 2014;94(2):383\u2013417.","journal-title":"Physiol Rev"},{"issue":"4","key":"4467_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/ki.2009.230","volume":"76","author":"L Huang","year":"2009","unstructured":"Huang L, Haylor JL, Hau Z, Jones RA, Vickers ME, Wagner B, et al. Transglutaminase Inhibition ameliorates experimental diabetic nephropathy. Kidney Int. 2009;76(4):383\u201394.","journal-title":"Kidney Int"},{"issue":"7","key":"4467_CR7","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3390\/cells10071842","volume":"10","author":"H Tatsukawa","year":"2021","unstructured":"Tatsukawa H, Hitomi K. Role of transglutaminase 2 in cell death, survival, and fibrosis. Cells. 2021;10(7):1842.","journal-title":"Cells"},{"issue":"24","key":"4467_CR8","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1111\/j.1742-4658.2011.08346.x","volume":"278","author":"AM Belkin","year":"2011","unstructured":"Belkin AM. Extracellular TG2: emerging functions and regulation. FEBS J. 2011;278(24):4704\u201316.","journal-title":"FEBS J"},{"issue":"2\u20133","key":"4467_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00726-011-1008-x","volume":"42","author":"Z Wang","year":"2012","unstructured":"Wang Z, Griffin M. TG2, a novel extracellular protein with multiple functions. Amino Acids. 2012;42(2\u20133):939\u201349.","journal-title":"Amino Acids"},{"issue":"10","key":"4467_CR10","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1681\/ASN.V10102146","volume":"10","author":"TS Johnson","year":"1999","unstructured":"Johnson TS, Skill NJ, El Nahas AM, Oldroyd SD, Thomas GL, Douthwaite JA, et al. Transglutaminase transcription and antigen translocation in experimental renal scarring. J Am Soc Nephrol. 1999;10(10):2146\u201357.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4467_CR11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41419-018-0573-2","volume":"9","author":"Z Wang","year":"2018","unstructured":"Wang Z, Stuckey DJ, Murdoch CE, Camelliti P, Lip GYH, Griffin M. Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor. Cell Death Dis. 2018;9(6):613.","journal-title":"Cell Death Dis"},{"issue":"8","key":"4467_CR12","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1097\/01.ASN.0000079614.63463.DD","volume":"14","author":"TS Johnson","year":"2003","unstructured":"Johnson TS, El-Koraie AF, Skill NJ, Baddour NM, El Nahas AM, Njloma M, et al. Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol. 2003;14(8):2052\u201362.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4467_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0168-8278(01)00135-0","volume":"35","author":"P Grenard","year":"2001","unstructured":"Grenard P, Bresson-Hadni S, El Alaoui S, Chevallier M, Vuitton DA, Ricard-Blum S. Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis. J Hepatol. 2001;35(3):367\u201375.","journal-title":"J Hepatol"},{"issue":"6","key":"4467_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1164\/rccm.201101-0013OC","volume":"184","author":"KC Olsen","year":"2011","unstructured":"Olsen KC, Sapinoro RE, Kottmann RM, Kulkarni AA, Iismaa SE, Johnson GV, et al. Transglutaminase 2 and its role in pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(6):699\u2013707.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"4467_CR15","first-page":"653","volume":"60","author":"M Griffin","year":"1979","unstructured":"Griffin M, Smith LL, Wynne J. Changes in transglutaminase activity in an experimental model of pulmonary fibrosis induced by Paraquat. Br J Exp Pathol. 1979;60(6):653\u201361.","journal-title":"Br J Exp Pathol"},{"issue":"1","key":"4467_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.matbio.2008.10.003","volume":"28","author":"M Fisher","year":"2009","unstructured":"Fisher M, Jones RA, Huang L, Haylor JL, El Nahas M, Griffin M, Johnson TS. Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring. Matrix Biol. 2009;28(1):20\u201331.","journal-title":"Matrix Biol"},{"issue":"12","key":"4467_CR17","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1093\/ndt\/gfq291","volume":"25","author":"L Huang","year":"2010","unstructured":"Huang L, Haylor JL, Fisher M, Hau Z, El Nahas AM, Griffin M, Johnson TS. Do changes in transglutaminase activity alter latent transforming growth factor beta activation in experimental diabetic nephropathy? Nephrol Dial Transpl. 2010;25(12):3897\u2013910.","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"4467_CR18","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1083\/jcb.136.5.1151","volume":"136","author":"I Nunes","year":"1997","unstructured":"Nunes I, Gleizes PE, Metz CN, Rifkin DB. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol. 1997;136(5):1151\u201363.","journal-title":"J Cell Biol"},{"key":"4467_CR19","doi-asserted-by":"publisher","first-page":"107787","DOI":"10.1016\/j.pharmthera.2020.107787","volume":"222","author":"J Prat-Duran","year":"2021","unstructured":"Prat-Duran J, Pinilla E, N\u00f8rregaard R, Simonsen U, Buus NH. Transglutaminase 2 as a novel target in chronic kidney disease - Methods, mechanisms and Pharmacological Inhibition. Pharmacol Ther. 2021;222:107787.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"4467_CR20","doi-asserted-by":"publisher","first-page":"e0262104","DOI":"10.1371\/journal.pone.0262104","volume":"17","author":"M Da Silva Lodge","year":"2022","unstructured":"Da Silva Lodge M, Pullen N, Pereira M, Johnson TS. Urinary levels of pro-fibrotic transglutaminase 2 (TG2) May help predict progression of chronic kidney disease. PLoS ONE. 2022;17(1):e0262104.","journal-title":"PLoS ONE"},{"issue":"12","key":"4467_CR21","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1681\/ASN.2006070690","volume":"18","author":"TS Johnson","year":"2007","unstructured":"Johnson TS, Fisher M, Haylor JL, Hau Z, Skill NJ, Jones R, et al. Transglutaminase Inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol. 2007;18(12):3078\u201388.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4467_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2353\/ajpath.2008.080025","volume":"173","author":"N Shweke","year":"2008","unstructured":"Shweke N, Boulos N, Jouanneau C, Vandermeersch S, Melino G, Dussaule JC, et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol. 2008;173(3):631\u201342.","journal-title":"Am J Pathol"},{"issue":"8","key":"4467_CR23","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1084\/jem.20101457","volume":"208","author":"K Oh","year":"2011","unstructured":"Oh K, Park HB, Byoun OJ, Shin DM, Jeong EM, Kim YW, et al. Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice. J Exp Med. 2011;208(8):1707\u201319.","journal-title":"J Exp Med"},{"issue":"11","key":"4467_CR24","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1111\/bph.15774","volume":"179","author":"M Maamra","year":"2022","unstructured":"Maamra M, Benayad OM, Matthews D, Kettleborough C, Atkinson J, Cain K, et al. Transglutaminase 2: development of therapeutic antibodies reveals four inhibitory epitopes and confirms extracellular function in fibrotic remodelling. Br J Pharmacol. 2022;179(11):2697\u2013712.","journal-title":"Br J Pharmacol"},{"issue":"13","key":"4467_CR25","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1096\/fasebj.13.13.1787","volume":"13","author":"ZA Haroon","year":"1999","unstructured":"Haroon ZA, Hettasch JM, Lai TS, Dewhirst MW, Greenberg CS. Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J. 1999;13(13):1787\u201395.","journal-title":"FASEB J"},{"issue":"2","key":"4467_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/0304-4165(88)90014-1","volume":"967","author":"JM Bowness","year":"1988","unstructured":"Bowness JM, Tarr AH, Wong T. Increased transglutaminase activity during skin wound healing in rats. Biochim Biophys Acta. 1988;967(2):234\u201340.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"4467_CR27","doi-asserted-by":"publisher","first-page":"e0298864","DOI":"10.1371\/journal.pone.0298864","volume":"19","author":"L Huang","year":"2024","unstructured":"Huang L, Bon H, Maamra M, Holmes T, Atkinson J, Cain K, et al. The effect of TG2-inhibitory monoclonal antibody zampilimab on tissue fibrosis in human in vitro and primate in vivo models of chronic kidney disease. PLoS ONE. 2024;19(5):e0298864.","journal-title":"PLoS ONE"},{"issue":"4","key":"4467_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ame2.12185","volume":"4","author":"L Huang","year":"2021","unstructured":"Huang L, Ni J, Duncan T, Song Z, Johnson TS. Development of a unilateral ureteral obstruction model in cynomolgus monkeys. Anim Model Exp Med. 2021;4(4):359\u201368.","journal-title":"Anim Model Exp Med"},{"issue":"26","key":"4467_CR29","doi-asserted-by":"publisher","first-page":"17699","DOI":"10.1074\/jbc.M513538200","volume":"281","author":"Y Sugimura","year":"2006","unstructured":"Sugimura Y, Hosono M, Wada F, Yoshimura T, Maki M, Hitomi K. Screening for the preferred substrate sequence of transglutaminase using a phage-displayed peptide library: identification of peptide substrates for TGASE 2 and factor XIIIA. J Biol Chem. 2006;281(26):17699\u2013706.","journal-title":"J Biol Chem"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04467-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:23:48Z","timestamp":1769091828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04467-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4467"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04467-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ownership of the animals used in this study resided with Prisys Biotechnologies (Shanghai, China), who also undertook the animal work, which was approved by the Institutional Animal Care and Use Committee under study number 2015-PS11-002 (license code No. 204 0000037). UCB representatives (including an animal care and welfare officer) assessed facilities and procedures prior to the study start to ensure best practice animal welfare in accordance with United Kingdom (UK) Home Office guidelines and the Animal Scientific Procedures Act 1986 (ASPL). A UCB representative was present during all animal experiments to ensure compliance with ASPL. The study is reported in accordance with the ARRIVE guidelines. The human skin biopsy study was a research collaboration with the University of Oxford and was approved by the South Central - Oxford B Research Ethics Committee (reference 16\/SC\/0457), in accordance with the Declaration of Helsinki. All participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RB is an employee of UCB who in-licensed zampilimab and holds\/has access to stock options. LH, TS, GIJ, and TSJ were employees of UCB at the time the work was completed and held\/had access to stock options during this time. TSJ is an inventor on patent WO2013\/175229 A1 (Anti-transglutaminase 2 antibodies) relating to the discovery and humanization of zampilimab. AB was an employee of OracleBio at the time the study was conducted. AR was an employee of Veramed at the time the study was conducted. GO is supported by the UK Medical Research Council and was in receipt of UCB research funding administered through the University of Oxford.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}